{"id":"cdk-4-6-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CDK4/6 inhibitors are small molecules that bind to and inhibit cyclin-dependent kinases 4 and 6, enzymes critical for driving cells from G1 phase into S phase of the cell cycle. By preventing retinoblastoma protein phosphorylation, these inhibitors cause cell cycle arrest in cancer cells, particularly in hormone receptor-positive breast cancer. This mechanism is often used in combination with endocrine therapy to enhance anti-tumor activity.","oneSentence":"CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression at the G1/S checkpoint.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:13.471Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer (likely indication based on CDK4/6 inhibitor class)"}]},"trialDetails":[{"nctId":"NCT07492641","phase":"PHASE3","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-05-11","conditions":"HR+/HER2- Breast Cancer","enrollment":1056},{"nctId":"NCT06994377","phase":"","title":"Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-25","conditions":"Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT07123090","phase":"PHASE2","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Stephanie Berg","startDate":"2025-11-24","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma","enrollment":25},{"nctId":"NCT06413706","phase":"PHASE2","title":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-25","conditions":"Glioma","enrollment":45},{"nctId":"NCT06016738","phase":"PHASE3","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2023-11-16","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":510},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT07227233","phase":"PHASE2","title":"Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-04","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT03170206","phase":"PHASE1","title":"Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-05-31","conditions":"Lung Cancer","enrollment":34},{"nctId":"NCT06586957","phase":"PHASE1","title":"A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"NiKang Therapeutics, Inc.","startDate":"2024-09-19","conditions":"Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult","enrollment":150},{"nctId":"NCT02499146","phase":"PHASE1","title":"Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-11","conditions":"Advanced Breast Cancer","enrollment":26},{"nctId":"NCT07252726","phase":"PHASE4","title":"Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2026-02-02","conditions":"Metastatic Breast Cancer, Metastatic Prostate Cancer","enrollment":50},{"nctId":"NCT06810544","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","status":"RECRUITING","sponsor":"Tango Therapeutics, Inc.","startDate":"2025-03-24","conditions":"Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant","enrollment":191},{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT04968964","phase":"NA","title":"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-03-07","conditions":"Breast Cancer, Cancer of the Breast","enrollment":55},{"nctId":"NCT05365178","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-07-01","conditions":"HR-positive, HER2-negative Breast Neoplasms","enrollment":432},{"nctId":"NCT06408168","phase":"PHASE2","title":"Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-08","conditions":"Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma","enrollment":6},{"nctId":"NCT04750928","phase":"PHASE1, PHASE2","title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-29","conditions":"Neurofibromatosis 1","enrollment":55},{"nctId":"NCT03090165","phase":"PHASE1, PHASE2","title":"Ribociclib and Bicalutamide in AR+ TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kari Wisinski","startDate":"2018-05-07","conditions":"Triple Negative Breast Cancer","enrollment":37},{"nctId":"NCT03285412","phase":"PHASE2","title":"CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-12-12","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT06851442","phase":"PHASE1, PHASE2","title":"Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-05-16","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT01723774","phase":"PHASE2","title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-10","conditions":"Breast Neoplasms","enrollment":84},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT04597580","phase":"","title":"Personalised Disease Monitoring in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2019-05-08","conditions":"Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer","enrollment":97},{"nctId":"NCT05266105","phase":"PHASE1","title":"A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2021-12-10","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT05496569","phase":"PHASE2","title":"TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-08","conditions":"Dedifferentiated Liposarcoma","enrollment":26},{"nctId":"NCT04116541","phase":"PHASE2","title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2020-01-28","conditions":"Malignant Solid Tumor","enrollment":455},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT05935748","phase":"PHASE2","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","status":"TERMINATED","sponsor":"NiKang Therapeutics, Inc.","startDate":"2023-07-28","conditions":"ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer","enrollment":18},{"nctId":"NCT07191717","phase":"PHASE2","title":"Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-04-30","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":42},{"nctId":"NCT07137871","phase":"PHASE1","title":"Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-10-02","conditions":"Breast Cancer Metastatic","enrollment":35},{"nctId":"NCT07223476","phase":"","title":"Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-29","conditions":"Breast Cancer","enrollment":1926},{"nctId":"NCT02297438","phase":"PHASE3","title":"A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-03-23","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT07195227","phase":"PHASE2","title":"Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2025-12-01","conditions":"Hormon Receptor Positive Breast Cancer, Breast Cancer","enrollment":150},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT06264921","phase":"PHASE1","title":"A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"NiKang Therapeutics, Inc.","startDate":"2024-02-23","conditions":"Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor","enrollment":23},{"nctId":"NCT02514447","phase":"PHASE1, PHASE2","title":"Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2015-10-05","conditions":"Small Cell Lung Cancer","enrollment":123},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT04887831","phase":"PHASE2","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-06-04","conditions":"Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult","enrollment":92},{"nctId":"NCT05874401","phase":"PHASE4","title":"Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan","status":"RECRUITING","sponsor":"Pharmacosmos A/S","startDate":"2023-10-18","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":302},{"nctId":"NCT04553133","phase":"PHASE2","title":"PF-07104091 as a Single Agent and in Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-09-16","conditions":"Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer","enrollment":154},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT03439735","phase":"PHASE2","title":"Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-07-20","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT06344793","phase":"","title":"Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-05-20","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT03675893","phase":"PHASE2","title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-12-24","conditions":"Endometrial Cancer, Ovarian Cancer","enrollment":180},{"nctId":"NCT07008508","phase":"","title":"Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-05-15","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT06947811","phase":"PHASE1, PHASE2","title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-09","conditions":"EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor","enrollment":71},{"nctId":"NCT04251169","phase":"PHASE2","title":"Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression","status":"TERMINATED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2020-07-21","conditions":"Metastatic Breast Cancer","enrollment":20},{"nctId":"NCT06996093","phase":"PHASE3","title":"Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-02","conditions":"Breast Cancer","enrollment":2508},{"nctId":"NCT05190094","phase":"PHASE2","title":"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.","status":"RECRUITING","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2022-12-20","conditions":"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer","enrollment":80},{"nctId":"NCT05621837","phase":"","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2022-03-10","conditions":"Melanoma, Breast Cancer, Renal Cell Carcinoma","enrollment":1000},{"nctId":"NCT02040857","phase":"PHASE2","title":"Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-01","conditions":"Breast Cancer","enrollment":162},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT06882499","phase":"NA","title":"Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II","status":"NOT_YET_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2025-05-01","conditions":"Breast Cancer, Metastatic, Metastatic Breast Cancer","enrollment":74},{"nctId":"NCT04660435","phase":"","title":"To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2020-09-01","conditions":"Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":150},{"nctId":"NCT05178888","phase":"PHASE1","title":"Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2022-01-20","conditions":"Advanced Solid Tumor","enrollment":11},{"nctId":"NCT05113966","phase":"PHASE2","title":"Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-12-08","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06147232","phase":"PHASE2","title":"Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia","status":"NOT_YET_RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2025-02","conditions":"Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1","enrollment":69},{"nctId":"NCT06702618","phase":"PHASE2","title":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-01","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT05293964","phase":"PHASE1","title":"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2022-05-18","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT04607668","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity","enrollment":326},{"nctId":"NCT02530320","phase":"PHASE2","title":"Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2015-10-25","conditions":"Oligodendroglioma, Oligoastrocytoma","enrollment":34},{"nctId":"NCT06044623","phase":"PHASE3","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-01","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life","enrollment":495},{"nctId":"NCT05262400","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-14","conditions":"Breast Cancer, Solid Tumors","enrollment":192},{"nctId":"NCT01740427","phase":"PHASE3","title":"A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02-22","conditions":"Breast Neoplasms","enrollment":666},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT05437419","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Teijin America, Inc.","startDate":"2022-08-10","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT01394016","phase":"PHASE1","title":"A Phase 1 Study of LY2835219 In Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-12-07","conditions":"Advanced Cancer","enrollment":225},{"nctId":"NCT05655598","phase":"PHASE1","title":"TAS-116 Plus Palbociclib in Breast and Rb-null Cancer","status":"WITHDRAWN","sponsor":"Brown University","startDate":"2023-09-12","conditions":"Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency","enrollment":""},{"nctId":"NCT06569459","phase":"PHASE2","title":"Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-09","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT06558084","phase":"","title":"Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-07-06","conditions":"Toxicity, Drug, Progression, Disease","enrollment":64},{"nctId":"NCT04799249","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-05-14","conditions":"TNBC - Triple-Negative Breast Cancer, Breast Cancer","enrollment":194},{"nctId":"NCT05923411","phase":"PHASE1","title":"A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-11","conditions":"Healthy Participants","enrollment":113},{"nctId":"NCT06481956","phase":"PHASE2","title":"T-DM1 Combined With CDK4/6 Inhibitor Ribociclib","status":"ENROLLING_BY_INVITATION","sponsor":"Zheng Yabing","startDate":"2023-10-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":40},{"nctId":"NCT02344472","phase":"PHASE3","title":"Detect V / CHEVENDO (Chemo vs. Endo)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":271},{"nctId":"NCT03434262","phase":"PHASE1","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-03-05","conditions":"Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma","enrollment":68},{"nctId":"NCT05431153","phase":"PHASE1","title":"A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT06332287","phase":"PHASE2","title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2023-05-01","conditions":"NSCLC","enrollment":25},{"nctId":"NCT05112536","phase":"PHASE2","title":"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2022-03-03","conditions":"Triple Negative Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154},{"nctId":"NCT06151262","phase":"PHASE2","title":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-01-20","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT04869943","phase":"PHASE3","title":"Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-10-12","conditions":"Metastatic Breast Cancer","enrollment":52},{"nctId":"NCT03386929","phase":"PHASE1, PHASE2","title":"Survival Prolongation by Rationale Innovative Genomics","status":"TERMINATED","sponsor":"Worldwide Innovative Network Association","startDate":"2017-11-29","conditions":"Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB","enrollment":15},{"nctId":"NCT01864746","phase":"PHASE3","title":"A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2013-10-30","conditions":"Breast Cancer, Hormonreceptor Positive, Her2-normal","enrollment":1250},{"nctId":"NCT02422615","phase":"PHASE3","title":"Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-09","conditions":"Advanced Breast Cancer","enrollment":726},{"nctId":"NCT06149611","phase":"PHASE1","title":"Mass Balance Study of TQB3616","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-01","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT05905341","phase":"PHASE1","title":"Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-01-15","conditions":"Breast Cancer, Ovarian Cancer, Liposarcoma","enrollment":""},{"nctId":"NCT04247126","phase":"PHASE1","title":"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Syros Pharmaceuticals","startDate":"2020-01-23","conditions":"Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer","enrollment":105},{"nctId":"NCT03803761","phase":"PHASE1, PHASE2","title":"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":""},{"nctId":"NCT05135104","phase":"","title":"Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period","status":"UNKNOWN","sponsor":"Asociatia Oncohelp - Centrul de Oncologie Oncohelp","startDate":"2021-12-15","conditions":"Metastatic Breast Cancer","enrollment":650},{"nctId":"NCT03455829","phase":"PHASE1, PHASE2","title":"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2018-03-29","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05780567","phase":"PHASE3","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-30","conditions":"Breast Cancer","enrollment":1946},{"nctId":"NCT04863248","phase":"PHASE2","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-04-30","conditions":"Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer","enrollment":10},{"nctId":"NCT05079360","phase":"PHASE2","title":"Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Veru Inc.","startDate":"2023-03-15","conditions":"Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT03447132","phase":"PHASE3","title":"Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant","status":"COMPLETED","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2017-12-20","conditions":"Breast Neoplasm Female","enrollment":354},{"nctId":"NCT02983071","phase":"PHASE1, PHASE2","title":"G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"G1 Therapeutics, Inc.","startDate":"2017-01","conditions":"Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":255,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ET","Palbociclib；","Abemaciclib / Ribociclib / Palbociclib"],"phase":"phase_3","status":"active","brandName":"(CDK)4/6 inhibitor","genericName":"(CDK)4/6 inhibitor","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression at the G1/S checkpoint. Used for Hormone receptor-positive, HER2-negative breast cancer (likely indication based on CDK4/6 inhibitor class).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}